Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Codeine + platycodon is a combination drug consisting of codeine, an opioid analgesic and antitussive, and platycodon (typically as Platycodon grandiflorus extract), a traditional herbal expectorant. This combination is primarily used for the symptomatic treatment of cough and difficult sputum expectoration in conditions such as upper respiratory tract inflammation and acute bronchitis. Codeine acts mainly by binding to mu-opioid receptors in the central nervous system to suppress cough reflexes and relieve mild to moderate pain. Platycodon is believed to exert its effects by promoting mucus secretion, facilitating sputum expulsion, and possibly providing anti-inflammatory benefits[4][1]. The combination leverages both the central antitussive action of codeine and the peripheral expectorant effect of platycodon.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on codeine + platycodon.